Novo Nordisk agreeing to sell its drugs [on the Hims platform]... Traders are looking optimistic that it will [get over the line]. Securing a partnership to sell highly coveted, branded GLP-1 weight-loss drugs directly addresses previous supply and copycat concerns, providing a massive catalyst for user acquisition, retention, and revenue growth for the telehealth platform. LONG Regulatory scrutiny over telehealth prescriptions or supply chain bottlenecks from Novo Nordisk could hinder the rollout.